drugset
drugset / Trial / NCT02784795

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795 ↗

Phase 1 Terminated 94 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

Timeline

Start
2016-11-04
Primary completion
2018-08-09
Completion
2020-02-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 100 mg Oral
Subject Abemaciclib Small molecule 150 mg Oral
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Samotolisib Small molecule 150 mg Oral
Subject Samotolisib Small molecule 200 mg Oral
Subject crenigacestat Small molecule 25 mg Oral
Subject crenigacestat Small molecule 50 mg Oral
Subject taladegib Small molecule 200 mg Oral

Indications

breast cancer cholangiocarcinoma colon carcinoma soft tissue sarcoma